SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

被引：0
|
作者：
Mahmoud Al Rifai
L. Kristin Newby
Ajith P. Nair
Arunima Misra
Joseph G. Rogers
Savitri Fedson
Salim S. Virani
机构：
[1] Baylor College of Medicine,Section of Cardiology, Department of Medicine
[2] Duke University School of Medicine,Department of Medicine, Division of Cardiology
[3] Duke University School of Medicine,Duke Clinical Research Institute
[4] Texas Heart Institute,Division of Cardiology
[5] Section of Cardiology,undefined
[6] Michael E. DeBakey Veterans Affairs Medical Center,undefined
来源：
Current Atherosclerosis Reports | 2022年 / 24卷
关键词：
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i); Heart failure (HF); Heart failure with preserved ejection fraction (HFpEF); Heart failure with reduced ejection fraction (HFrEF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：627 / 634
页数：7
相关论文
共 50 条
  • [1] SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai, Mahmoud
    Newby, L. Kristin
    Nair, Ajith P.
    Misra, Arunima
    Rogers, Joseph G.
    Fedson, Savitri
    Virani, Salim S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (08) : 627 - 634
  • [2] Heart failure: SGLT-2 inhibitors have multiple benefits
    Heinzl, Susanne
    DIABETES STOFFWECHSEL UND HERZ, 2024, 33 (04):
  • [3] SGLT-2 inhibitors in frail patients with heart failure
    Charansonney, Olivier Luc
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 352 : 102 - 103
  • [4] The use of SGLT-2 inhibitors and hemoconcentration in patients with heart failure
    Demir, E.
    Kose, R.
    Pirmammadova, F.
    Unlugenc, H.
    Gurgun, C.
    Nalbantgil, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 219 - 220
  • [5] Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
    Cavallari, Ilaria
    Maddaloni, Ernesto
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (04)
  • [6] When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Sharma, Aditya
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (04) : 208 - 208
  • [7] When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Badwan, Osamah Z.
    Braghieri, Lorenzo
    Skoza, Warren
    Agrawal, Ankit
    Menon, Venu
    Tang, W. H. Wilson
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (01) : 47 - 51
  • [8] SGLT-2 Inhibitors in Heart Failure Volume or Value?
    Kosiborod, Mikhail N.
    Vaduganathan, Muthiah
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (11) : 1393 - 1396
  • [9] Clinical pharmacology of SGLT-2 inhibitors in heart failure
    Velliou, Maria
    Polyzogopoulou, Effie
    Ventoulis, Ioannis
    Parissis, John
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (02) : 149 - 160
  • [10] SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys
    Verbrugge F.H.
    Martens P.
    Mullens W.
    Current Heart Failure Reports, 2017, 14 (4) : 331 - 337
12345